AbbVie is a high-yield healthcare name with a 2.66% dividend, but its F valuation grade makes it one of the least cheap stocks in this entire batch. A ~72x P/E reflects strong expectations for its post-Humira pipeline (Skyrizi, Rinvoq) to keep delivering growth.

Both growth (A-) and profitability (A) grade well, so the fundamentals are solid, but investors should recognize the stock has already priced in much of that growth. The right approach here is weighing the dividend appeal against a genuinely stretched valuation.